Weight Loss
Research Peptides
Research peptides studied for fat metabolism, appetite regulation, and energy expenditure. Tirzepatide, Retatrutide, AOD-9604, Fragment 176-191. +99% purity, COA every batch.
All Weight Loss Research Peptides
Adipotide Nasal Spray
Adipotide Peptide Vial
Adipotide Pre-Mixed Peptide
AOD-9604 BPC-157 Peptide Stack
AOD-9604 Nasal Spray
AOD-9604 Peptide Vial
AOD-9604 Pre-Mixed Peptide
CJC-1295 DAC HGH Frag 176-191 Pre-Mixed Peptide
HGH Frag 176-191 CJC-1295 DAC Blend
HGH Frag 176-191 CJC-1295 DAC Nasal Spray
HGH Frag 176-191 CJC-1295 No DAC Nasal Spray
HGH Fragment 176-191 Nasal Spray
HGH Fragment 176-191 Peptide Vial
HGH Fragment 176-191 Pre-Mixed Peptide
Ipamorelin HGH Frag 176-191 CJC-1295 DAC Blend
Ipamorelin HGH Frag 176-191 CJC-1295 No DAC Blend
Tesamorelin Nasal Spray
Tesamorelin Peptide Vial
Tesamorelin Pre-Mixed Peptide
Tesofensine Capsules
Researching metabolic protocols?
Use the Stack Builder to match your goal to the right protocol.
Frequently Asked Questions
What are weight loss research peptides?
Weight loss research peptides are compounds studied for their effects on fat metabolism, appetite regulation, and energy expenditure in preclinical models. The most extensively studied include GLP-1 receptor agonists (Tirzepatide, Retatrutide, Semaglutide), GH fragment peptides (AOD-9604, Fragment 176-191), and metabolic regulators (AICAR, MOTS-c). All are supplied For Research Use Only and are not approved for human weight loss treatment.
What is the difference between Tirzepatide and Retatrutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, it activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Retatrutide is a triple agonist: GIP, GLP-1, and glucagon receptor. In Phase II clinical trials, Retatrutide demonstrated greater mean bodyweight reduction than tirzepatide at comparable doses, owing to the additional glucagon-mediated increase in energy expenditure. Both remain active research compounds..
What is AOD-9604 and how does it relate to fat metabolism research?
AOD-9604 (Advanced Obesity Drug-9604) is a synthetic fragment of human growth hormone encompassing the lipolytic region (hGH176-191) without the anabolic IGF-1–stimulating domain. In preclinical models it activates beta-adrenergic receptors in adipocytes to stimulate lipolysis and inhibits lipogenesis, without raising blood glucose or IGF-1 levels. Fragment 176-191 is a related compound representing the same region, studied for its selective fat-targeting mechanism.
What formats are weight loss peptides available in?
Stackpure supplies weight loss research peptides in multiple formats: lyophilised injectable vials (requiring reconstitution with bacteriostatic water), pre-mixed ready-to-use liquid solutions, nasal spray formulations, and oral capsule formats where applicable. GLP-1 agonists like Tirzepatide and Retatrutide are typically available as vials. AOD-9604 and Fragment 176-191 are available across multiple formats. Choose the format that best suits your research protocol.
Do you ship weight loss research peptides internationally?
Yes. Stackpure ships research peptides to the USA, UK, Canada, and Australia. All orders include a third-party COA confirming identity and purity. Delivery is 1–3 business days to the USA, UK, Canada, and Australia. Buyers are responsible for compliance with local import regulations.